SEC Form 4 · accession 0001179110-18-011567

RIGEL PHARMACEUTICALS INC · RIGL

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP & Chief Medical Officer

Period of report

Sep 17, 2018

Accepted (ET)

Sep 19, 2018 · 6:26 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001034842

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Sep 17, 2018	M	115,500	$2.54	A	115,500	D
Common Stock^F1	Sep 17, 2018	S	115,500	$3.50	D	0	D
Common Stock	Sep 17, 2018	M	37,500	$2.11	A	37,500	D
Common Stock^F1	Sep 17, 2018	S	37,500	$3.50	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employe Stock Option (right to buy)^F2	$2.54	Sep 17, 2018	M	115,500	D	—	May 5, 2026	Common Stock	115,500	268,000	D
Employee Stock Option (right to buy)^F3	$2.11	Sep 17, 2018	M	37,500	D	—	Feb 2, 2027	Common Stock	37,500	112,500	D

F1The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018.
F2One fourth (1/4th) of the option vests one (1) year from March 7, 2016 and thereafter the balance of the option vests in equal monthly installments over the next thirty-six (36) months.
F3The shares vest over four (4) years from January 1, 2017.